Skip to content
AnalystLens

BridgeBio Pharma Annual Report, Year Ended Dec 31, 2021

Filing Date
Filed February 25, 2022
Period End
December 31, 2021
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Deal closed8-K · Jan ’21Jan ’21
  2. Material agreement8-K · Sep ’23Sep ’23
  3. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 10-K filed February 25, 2022. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. reported a net loss of $586.5 milliona for the year ended December 31, 2021, compared with $505.5 million in 2020 and $288.6 million in 2019, and an accumulated deficit of $1.4 billion.

Total revenue was $69.7 millionb in 2021, consisting of $65.9 million in license revenue and $3.8 million in product sales, following $8.2 million in 2020. Research and development expenses rose to $451.0 million from $337.0 million, and selling, general and administrative expenses rose to $192.2 million from $145.7 million. The company had cash, cash equivalents and marketable securities of $787.5 million and an investment in equity securities of $49.1 million at year-end, and states it expects these to fund operations for at least the next 12 months.

The company has two approved products, NULIBRY (fosdenopterin) and TRUSELTIQ (infigratinib). Its most significant pipeline event in the filing is the December 27, 2021 topline report that acoramidis missed its Part A primary endpoint at Month 12 (6MWD change, p = 0.76) in the Phase 3 ATTRibute-CM study. The company continues to expect top-line 30-month Part B outcomes in mid-2023.

Other near-term catalysts described include PROPEL 2 initial infigratinib data in mid-2022, BBP-631 initial Phase 1/2 data in the second half of 2022, and BBP-418 Phase 2 top-line data in 2022. At year-end the company had total consolidated indebtedness of $1.7 billionc, including $747.5 million of 2.25% convertible notes due 2029, $550.0 million of 2.50% convertible notes due 2027, and $450.0 million drawn under a November 2021 loan agreement, with a further $300.0 million tranche available until December 31, 2022 subject to clinical milestones. The filing also notes a $150.0 million share repurchase program completed in 2021 and that the Eidos Merger, closed January 26, 2021, was settled with approximately 26.2 million shares and $21.3 million in cash.

Key Highlights

  1. Net loss of $586.5 million in 2021, up from $505.5 million in 2020; accumulated deficit of $1.4 billion at December 31, 2021.
  2. Total revenue of $69.7 million in 2021, including $65.9 million of license revenue (mainly from the QED-Helsinn agreement) and $3.8 million of product sales.
  3. Research and development expense rose to $451.0 million (from $337.0 million) and SG&A rose to $192.2 million (from $145.7 million).
  4. Acoramidis Phase 3 ATTRibute-CM Part A did not meet its primary 6MWD endpoint (p = 0.76); the company continues to anticipate top-line 30-month Part B data in mid-2023.
  5. Cash, cash equivalents and marketable securities of $787.5 million plus $49.1 million of equity securities; the company expects these to fund operations for at least 12 months.
  6. Total consolidated indebtedness of $1.7 billion, including $747.5 million of 2029 convertible notes, $550.0 million of 2027 convertible notes and $450.0 million of term loans.
  7. Two approved products, NULIBRY (FDA approval February 2021) and TRUSELTIQ (FDA accelerated approval May 2021), with over 30 development programs in the pipeline.

Financial Statements

FY2021 against FY2020

Line itemFY2021FY2020Change
Revenue$69.72M$8.25M+745.1%
Cost of Revenue$3.11M——
Gross Profit$66.60M——
R&D Expenses$451.02M$337.05M+33.8%
SG&A Expenses$192.21M$145.68M+31.9%
Operating Expenses$646.35M$482.73M+33.9%
Operating Income-$576.63M-$474.48M−21.5%
Interest Expense$46.78M$36.66M+27.6%
Net Income-$562.54M-$448.72M−25.4%
EPS (Basic)$-3.90$-3.80−2.6%
EPS (Diluted)$-3.90$-3.80−2.6%
Shares Outstanding (Basic)144.36M118.00M+22.3%
Shares Outstanding (Diluted)144.36M118.00M+22.3%

Frequently Asked Questions

  1. Why did the acoramidis Phase 3 trial miss its primary endpoint, and what happens next?

    On December 27, 2021, the company reported that Part A of the ATTRibute-CM study did not meet its change-from-baseline 6MWD primary endpoint at Month 12 (p = 0.76). Mean 6MWD declines were 9 meters for acoramidis and 7 meters for placebo, which the filing describes as similar to healthy elderly adults. The company reported improvements versus placebo on KCCQ-OS, NT-proBNP and serum TTR at Month 12. The independent data monitoring committee recommended continuing the study through Month 30, and the company anticipates reporting top-line Part B outcomes in mid-2023.

  2. How much cash does the company have and how long will it last?

    At December 31, 2021, cash, cash equivalents and marketable securities totaled $787.5 million, and the company held $49.1 million of investment in equity securities. The company states it expects these resources to fund operations for at least the next 12 months, while noting that its operating plans may change and it may need additional funding sooner through equity, debt, or collaborations.

  3. What debt obligations does BridgeBio carry?

    Total consolidated indebtedness was $1.7 billion at December 31, 2021: $747.5 million of 2.25% convertible senior notes due 2029, $550.0 million of 2.50% convertible senior notes due 2027, and $450.0 million under a November 2021 loan agreement bearing a fixed 9.0% rate (3.00% of which may be paid in kind), maturing November 17, 2026. An additional $300.0 million tranche is available until December 31, 2022, subject to clinical milestone events. The loan agreement contains operating covenants and restricts dividends.

  4. What drove the increase in operating expenses in 2021?

    Research and development expense increased by $114.0 million to $451.0 million, due mainly to higher personnel costs from headcount growth and stock-based compensation tied to milestones, and higher external manufacturing costs. Selling, general and administrative expense increased by $46.5 million to $192.2 million, reflecting organizational growth and the staged build-out of the commercial organization. Helsinn's $38.4 million share of infigratinib R&D costs partially offset R&D expense.

  5. What are the key near-term catalysts described in the filing?

    The filing anticipates initial data from PROPEL 2 (low-dose infigratinib in achondroplasia) in mid-2022, initial data from the Phase 1/2 BBP-631 trial for congenital adrenal hyperplasia in the second half of 2022, top-line data from the Phase 2 BBP-418 trial in 2022, complete results from the encaleret Phase 2b study in 2022 with a planned Phase 3 start in 2022, and the 30-month acoramidis Part B outcomes in mid-2023.